Investor Relations

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s Fantom Encore bioresorbable vascular scaffold is CE Mark approved for the treatment of coronary artery disease and available in select European and Middle Eastern countries. The MOTIV bioresorbable scaffold, developed for the treatment of peripheral vascular disease in arteries below the knee, received CE Mark approval in July of 2018. The Company is also leveraging its proprietary polymer technology to develop novel products for the field of embolization therapy. Its first effort will focus on the development of x-ray visible, bioresorbable embolic beads for the treatment of vascularized tumors, such as hepatocellular carcinoma, uterine fibroids, and benign prostatic hyperplasia.

REVA is a Delaware corporation with its corporate headquarters located in San Diego, California. REVA securities are traded on the Australian Securities Exchange ("ASX") under the symbol RVA. REVA’s international ticker symbol is RVA.AX. Its securities trade in the form of CHESS Depositary Interests ("CDIs"). The Company is also registered with the United States Securities and Exchange Commission (“SEC”), however its securities are currently not traded on NASDAQ or the New York Stock Exchange.

Jan 19, 2020 12:54 AM EST

Copyright Nasdaq. Minimum 15 minutes delayed.
10 CDIs equivalent to one share of common stock